Avecho Biotechnology Limited · LS:A2PLEV

Avecho Biotechnology Limited financial statements

Avecho Biotechnology Limited's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.24M1.13M473.6K1.13M793.6K384.6K4.24M1.25M1.15M1.59M
Cost of revenue486.5K460.7K517.3K336.1K285.7K143.7K1.85M553.3K93.8K329.2K
Gross profit751.3K671.9K-43.8K793.1K507.9K240.9K4.02M699.0K1.06M1.26M
Research and development4.31M3.59M2.12M1.59M2.13M187.6K166.0K1.03M2.27M2.83M
Selling, general and administrative2.07M1.99M2.43M1.49M2.83M2.74M1.29M1.32M4.41M3.88M
Operating income-6.00M-4.96M-4.59M-3.06M-4.55M-3.39M1.57M-5.33M-9.06M-9.29M
Depreciation and amortization137.1K144.9K178.7K230.4K428.6K536.6K683.5K725.6K776.5K2.47M
EBITDA-5.87M-4.81M-4.41M-2.83M-4.12M-2.85M2.26M-4.60M-8.28M-6.82M
Interest expense461.4K57.1K15.4K6.35K9.97K5.92K11.0K90.5K36.0K110.0K
Income before tax-6.41M-3.12M-4.51M-2.96M-4.54M-3.00M503.9K-4.68M-9.63M-19.1M
Income tax-2.00M-1.64M-1.08M-623.0K-1.13M-360.0K-346.0K-685.0K-1.01M-1.83M
Net income-4.42M-3.12M-3.44M-2.34M-3.42M-2.63M850.0K-3.99M-8.62M-17.3M
Earnings per share, basic-0.00-0.00-0.00-0.00-0.00-0.000.00-0.00-0.01-0.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents4.66M2.37M5.50M1.47M3.26M1.87M3.21M2.11M2.90M6.09M
Short-term investments85.7K56.7K454.7K205.0K
Receivables2.20M2.25M1.10M746.0K1.13M479.1K755.4K292.3K212.3K274.3K
Inventory8.07K137.5K97.1K402.0K196.7K100.0K148.8K99.8K291.6K237.0K
Current assets7.06M4.81M7.00M2.85M4.81M2.69M4.28M3.25M5.80M10.2M
Property, plant and equipment33.7K170.8K315.7K468.1K336.2K233.0K179.9K159.6K251.0K384.9K
Total assets7.11M5.00M7.32M3.35M5.25M3.35M5.32M4.80M8.24M13.4M
Accounts payable103.7K60.6K94.9K191.2K75.2K110.3K96.6K132.4K1.08M571.0K
Current liabilities709.2K1.71M843.3K745.5K695.7K603.6K544.8K872.5K1.71M1.66M
Total debt14.5K1.08M175.2K246.1K93.9K166.2K97.2K
Total liabilities5.55M1.73M941.5K920.7K709.4K700.2K556.1K902.0K1.84M1.71M
Shareholders' equity1.56M3.27M6.38M2.42M4.54M2.65M4.76M3.90M6.40M11.6M
Shares outstanding3.27B3.12B2.27B1.84B1.80B1.59B1.58B1.57B1.30B1.29B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations1.10M-3.97M-3.18M-1.67M-3.10M-1.42M1.19M-2.19M-6.42M-6.41M
Capital spending00-5-53.1K-202.8K-5.15K-5.15K-424-55.6K-62.3K
Free cash flow1.10M-3.97M-3.18M-1.72M-3.30M-1.43M1.19M-2.19M-6.48M-6.47M
Cash from investing0-15.7K0-53.1K-202.8K-5.15K11.1K41.8K53.5K108.8K
Cash from financing1.19M854.6K7.22M-78.2K4.69M-82.5K-89.4K1.36M3.17M3.17M
Dividends paid-4.40M
Share buybacks-187.2K0-716.5K1.99K-294.2K0-13.5K-186.2K
Change in cash2.29M-3.13M4.04M-1.80M1.39M-1.34M1.10M-787.4K-3.19M-6.30M